XILIO THERAPEUTICS INC

Historical 13F Holders

Reported Value, Excluding Options

Total Filings

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 98422T209 since 12/18/2024, largest first.

Filer	% of Class	Shares	Form	Filed
Bain Capital Life Sciences Fund II, L.P. 13G/A	10.0%	664,021	13G/A	5/15/2026 Event 3/31/2026
BCLS II Equity Opportunities, LP	10.0%	664,021
Bain Capital Life Sciences Fund II, L.P.	0%	0
BCIP Life Sciences Associates, LP	0%	0
StemPoint Capital LP 13G/A	9.5%	628,866	13G/A	8/14/2026 Event 6/30/2026
StemPoint Capital LP	9.5%	628,866
StemPoint Capital Management GP LLC	9.5%	628,866
Michelle Ross	9.5%	628,866

Period	Filings	Shares, Excl. Options	Value, Excl. Options	Options Value
2026 Q2	26	2.76 M	$26.4 M	$0
2026 Q1	23	1.97 M	$16.6 M	$0